Pilot study [Power / Sample Size]

posted by konkous – Greece, 2020-12-11 08:25 (313 d 13:14 ago) – Posting: # 22140
Views: 1,065

Dear colleagues,

We have conducted an in-vitro permeation pilot study for confirming the suitability of our design in terms of time points, duration and for estimating the sample size for the pivotal study based on the within-reference %CV and the GMR calculated. The GMR was approximately 1.19 and the %CV around 25%. As it can easily be inferred the 90% C.I did not fall within the 0.80-1.25 interval. I realize that no safe conclusions can be drawn from a very small sample size regarding the equivalence of the products but i wonder if there is an established methodology for assessing if there is any point in proceeding with the pivotal study.

Thank you,

Best regards,

Constantinos


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

Activity
 Admin contact
21,749 posts in 4,547 threads, 1,545 registered users;
online 28 (0 registered, 28 guests [including 4 identified bots]).
Forum time: Wednesday 22:39 CEST (Europe/Vienna)

Mediocrity finds safety in standardization.    Frederick E. Crane

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5